Discontinued Operations (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 27, 2019	Dec. 28, 2018	Dec. 29, 2017	Nov. 04, 2019	Mar. 16, 2018	Mar. 17, 2017	Jan. 27, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operation, Tax Effect of Discontinued Operation	$ 1.7	$ 1.4	$ 5.4
Losses (gains) on divestiture	33.5	0.8	(56.9)
Nuclear Imaging
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Capital Expenditure, Discontinued Operations			0.3
Disposal Group, Including Discontinued Operations, Net Sales			31.6
Disposal Group, Including Discontinued Operation, Consideration							$ 690.0
Disposal Group, Including Discontinued Operation, Upfront Consideration							574.0
Disposal group, Including Discontinued Operation, Contingent Consideration Maximum Amount							$ 77.0
Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax			362.8
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax	9.0	15.0	8.4
Contingent consideration received, equity certificates	$ 9.0	9.0
Discontinued Operation, Amount of Adjustment to Prior Period Gain (Loss) on Disposal, Net of Tax		6.0
Interest Rate, Equity Certificates	10.00%
Disposal Group, Including Discontinued Operation, Costs of Goods Sold			15.6
Disposal Group, Including Discontinued Operation, General and Administrative Expense			7.8
Disposal Group, Including Discontinued Operation, Other Income			0.2
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax			371.2
Discontinued Operation, Tax Effect of Discontinued Operation			5.2
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax			366.0
BioVectra Inc [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Not Discontinued Operation, Consideration				$ 250.0
Disposal Group, Including Discontinued Operation, Upfront Consideration				135.0
Disposal Group, Not Discontinued Operation, Contingent Consideration				$ 115.0
Losses (gains) on divestiture	$ 33.5
Hemostasis Products
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Not Discontinued Operation, Consideration					$ 185.0
Disposal Group, Including Discontinued Operation, Upfront Consideration					153.0
Losses (gains) on divestiture		0.8
Disposal Group, Not Discontinued Operations, Account Receivable Consideration					13.7
Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent					$ 49.9
Goodwill, Period Increase (Decrease)		(51.5)
Intrathecal Therapy [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Not Discontinued Operation, Consideration						$ 203.0
Disposal Group, Not Discontinued Operation, Fixed Consideration						171.0
Disposal Group, Not Discontinued Operation, Contingent Consideration						32.0
Disposal Group, Not Discontinued Operation, Upfront Consideration						17.0
Disposal Group, Not Discontinued Operation, Note Receivable Consideration						154.0
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Pre-tax			56.6
Proceeds from Collection of Notes Receivable		154.0
Disposal Group, Not Discontinued Operation, Other Commitment	$ 2.1	$ 3.1				$ 7.3
Other Intangibles | Intrathecal Therapy [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Losses (gains) on divestiture			48.7
Goodwill [Member] | Intrathecal Therapy [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Losses (gains) on divestiture			$ 49.8